Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Production & Manufacturing
Return to: PBR Home | Production & Manufacturing | Manufacturing

Ranbaxy gains approval to manufacture RAN-Rosuvastatin tablets in Canada

PBR Staff Writer Published 02 April 2012

Ranbaxy Pharmaceuticals Canada (RPCI) has received Health Canada approval to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system.

Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication).

RPCI, a wholly owned subsidiary of Ranbaxy Laboratories, sells and distributes generic prescription products in the Canadian healthcare system.

RPCI Canada president and general manager Paul Drake said the finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India.

"We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," Drake added.